The Pfizer is accepting applications for PARP-Inhibitor Combination Treatments: Biomarker Testing, Safety, and Efficacy in a Rapidly Changing Metastatic Prostate Cancer (mPC) Landscape. Funding Information Individual projects requesting up to $350,000 will be considered. The estimated total available budget related to this RFP is $850,000. Award amounts include direct costs, institutional overhead costs (capped at
Access Restricted: Members-Only Content. We're sorry, but this content is available exclusively to our subscribed members: